An Overview
drugPRINTTM
The components of this technology, originally developed at QinetiQ
will form an exhaustive pre-clinical testing system for potential
pharmaceutical compounds.
It is designed to help identify structure-activity relationships in drugs and
should significantly reduce the number of compounds that fall in
toxicology and in early stage clinical development.
The system Is based on the use of micro-electrode array plate technology
and enables long term, non-invasive recordings to be made of the
electrical activity generated in cells forming a functional syncitium when
cultured on the plate.
The technology offers a unique insight into the integrated behaviour of
cells within an in vitro network, providing a robust platform for high
throughput drug screening.
The key features are as follows:
- Rapid characterisation and screening of drug compounds
- More efficient and effective experimentation
- Use of live cells and with reduced animal dependence
- Cost reduction in toxicology testing
- Long term, non-invasive monitoring
The system provides a finger print read-out characterising 39 features giving a reliable, consistent and biologically relevant series of results.
Although the system will be used initially in cardiovascular drug design and testing the technology is applicable to all organ types. As such it is an example of technology with much wider applications (often referred to as "platform technology").
VivoMedica’s DrugPrint could save drug recall casualties
"VivoMedica’s CEO Peter Leyland and Senior Scientist Simon Bryant were recently interviewed by Tina Tan of Clinica for a leading article in January Issue 1288. Peter and Simon discuss the rapid progress in the development of the DrugPrint platform and the successful poster presentation at the SPS meeting (Safety Pharmaceutical Society) that has led to significant interest among both drug and stem cell companies."
>> more infodrugPRINTTM goes to SPS:
drugPRINTTM presents at Safety Pharmacology Society.....
>> Download pdf file